Trade Viking Therapeutics, Inc. - VKTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 23.04 |
| Open | 22.67 |
| 1-Year Change | -66.11% |
| Day's Range | 22.61 - 22.84 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 15, 2025 | 23.04 | -1.35 | -5.54% | 24.39 | 24.55 | 22.60 |
| Apr 14, 2025 | 24.47 | -2.24 | -8.39% | 26.71 | 26.71 | 23.52 |
| Apr 11, 2025 | 22.15 | 0.68 | 3.17% | 21.47 | 22.33 | 21.11 |
| Apr 10, 2025 | 21.45 | -0.46 | -2.10% | 21.91 | 22.40 | 20.35 |
| Apr 9, 2025 | 23.00 | 3.51 | 18.01% | 19.49 | 23.54 | 18.87 |
| Apr 8, 2025 | 19.90 | -2.40 | -10.76% | 22.30 | 22.61 | 19.53 |
| Apr 7, 2025 | 21.21 | 0.49 | 2.36% | 20.72 | 22.90 | 20.21 |
| Apr 4, 2025 | 22.55 | -0.75 | -3.22% | 23.30 | 23.45 | 21.48 |
| Apr 3, 2025 | 24.17 | -0.09 | -0.37% | 24.26 | 25.81 | 24.03 |
| Apr 2, 2025 | 25.64 | 2.21 | 9.43% | 23.43 | 25.69 | 23.43 |
| Apr 1, 2025 | 23.86 | -0.19 | -0.79% | 24.05 | 24.46 | 23.25 |
| Mar 31, 2025 | 24.07 | -0.08 | -0.33% | 24.15 | 24.41 | 23.21 |
| Mar 28, 2025 | 25.59 | -0.21 | -0.81% | 25.80 | 26.13 | 25.15 |
| Mar 27, 2025 | 26.05 | -0.20 | -0.76% | 26.25 | 27.14 | 26.04 |
| Mar 26, 2025 | 26.27 | -1.38 | -4.99% | 27.65 | 28.10 | 25.75 |
| Mar 25, 2025 | 27.93 | -1.43 | -4.87% | 29.36 | 29.43 | 27.70 |
| Mar 24, 2025 | 29.23 | 0.35 | 1.21% | 28.88 | 29.52 | 28.15 |
| Mar 21, 2025 | 28.88 | 1.07 | 3.85% | 27.81 | 28.93 | 27.63 |
| Mar 20, 2025 | 28.29 | -1.47 | -4.94% | 29.76 | 30.65 | 28.28 |
| Mar 19, 2025 | 30.02 | 0.74 | 2.53% | 29.28 | 30.11 | 29.00 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Viking Therapeutics, Inc. Company profile
About Viking Therapeutics Inc
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Viking Therapeutics Inc revenues was not reported. Net loss increased 39% to $55M. Higher net loss reflects Other Research and Development. increase of 42% to $43.4M (expense), Interest Income - Net decrease of 78% to $703K (income), Stock-based Compensation in R&D increase of 19% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.54 to -$0.71.
| Industry: | Bio Therapeutic Drugs |
9920 Pacific Heights Blvd, Suite 350
SAN DIEGO
CALIFORNIA 92121
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com